Antibiotic Stewardship in der Dermatologie – Grundlagen und aktuelle Themen

C. S. L. Müller; T. Vogt; S. L. Becker

doi:10.1055/a-1011-1180

Aktuelle Dermatologie, Table of Contents

Aktuelle Dermatologie 2019; 45(12): 613-628
DOI: 10.1055/a-1011-1180

CME-Fortbildung

Antibiotic Stewardship in der Dermatologie – Grundlagen und aktuelle Themen

Antibiotic Stewardship in Dermatology – Basics and Current Topics

C. S. L. Müller

,

T. Vogt

,

S. L. Becker

Subject Editor: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Cornelia S. L. Müller, Homburg/Saar.

Abstract

Ziele einer gezielten rationalen Antibiotika-/Antiinfektivatherapie und damit einer gelungenen Arbeit von Antiobiotic Stewardship (ABS) sind beste klinische Therapieergebnisse, Minderung von Nebenwirkungen und Toxizität sowie eine Resistenzminimierung. In diesem Artikel sollen ABS-Strategien in der Dermatologie vorgestellt und exemplarisch an drei klinisch relevanten aktuellen Themen verdeutlicht werden.

Abstract

Aim of Antibiotic Stewardship (ABS) is to provide structured counseling as well as training and further education of all medical groups with regard to a rational anti-infective prescription practice. The use of anti-infective agents must be done carefully and rationally to counteract further resistance. In dermatology, too, antiinfectives play a major role in the therapy of various infectious and inflammatory diseases. The aim of this article is the presentation of ABS in general and with specific dermatological focus.

Schlüsselwörter

Antibiotic Stewardship - Resistenzen - Antiinfektiva - Dermatologie

Keywords

antibiotic stewardship - resistance - antiinfective agents - dermatology

Full Text

References

Literatur
1 Jensen RH. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Dan Med J 2016; 63: pii: B5288
2 Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genet Biol 2019; 132: 103255
3 Shishodia SK, Tiwari S, Shankar J. Resistance mechanism and proteins in Aspergillus species against antifungal agents. Mycology 2019; 10: 151-165
4 Conclusions of the European Union Conference on ‘The microbial threat’, 9–10 September 1998. The Copenhagen Recommendation. Ministry of Health Ministry of Food, Agriculture and Fisheries. Vet Res 1999; 30: 119-122
5 Frimodt-Moller N. Microbial Threat – The Copenhagen Recommendations initiative of the EU. J Vet Med B Infect Dis Vet Public Health 2004; 51: 400-402
6 EU Council. Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC). Official J Eur Commun L34: 13-16
7 Frimodt-Moller N. The international surveillance of antibiotics resistance. Ugeskr Laeger 2011; 173: 2880-2882
8 EU Action on Antimicrobial Resistance. Im Internet: https://ec.europa.eu/health/amr/antimicrobial-resistance_en
9 Abu Sin M, Nahrgang S, Ziegelmann A. et al. Globale und nationale Strategien gegen Antibiotikaresistenzen. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2018; 61: 507-514
10 de With K, Wilke K, Kern WV. et al. S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. AWMF-Registernummer 092–001, update 2018. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2019-04.pdf Stand: 20.11.2019
11 Sunderkotter C, Becker K. Frequent bacterial skin and soft tissue infections: diagnostic signs and treatment. J Dtsch Dermatol Ges 2015; 13: 501-524; quiz 525-506
12 Sunderkotter C, Becker K, Eckmann C. et al. S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for „calculated initial parenteral treatment of bacterial infections in adults – update 2018“. J Dtsch Dermatol Ges 2019; 17: 345-369
13 Bodmann KF, Grabein B, Kresken M. et al. für die Expertenkommission*. S2k Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen. AWMF-Registernummer 082-006. Im Internet: https://www.awmf.org/leitlinien/detail/ll/082–006.html (Stand: 12.11.2019)
14 Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis 2004; 74: 118-122
15 Dreno B. Topical antibacterial therapy for acne vulgaris. Drugs 2004; 64: 2389-2397
16 Patel M, Bowe WP, Heughebaert C. et al. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol 2010; 9: 655-664
17 Gollnick HP, Buer J, Beissert S. et al. Verantwortlicher Umgang mit Antibiotika: Notwendigkeit der Antibiotikareduktion in der Aknetherapie. J Dtsch Dermatol Ges 2016; 14: 1319-1327
18 Bae-Harboe YSC, Liang CA. Perioperative antibiotic use of dermatologic surgeons in 2012. Dermatologic Surgery 2013; 39: 1592-1601
19 Perioperative Antibiotikaprophylxe. AK „Krankenhaus- und Praxishygiene“ der AWMF 2012 Leitlinie 029-022. Im Internet: https://euprevent.eu/wp-content/uploads/2017/01/AWMF-Leitlinie-Perioperative-Antibiotikaprophylaxe.pdf
20 Reutter F, Reuter DA, Hilgarth H. et al. Perioperative Antibiotikaprophylaxe. Anaesthesist 2014; 63: 73-86
21 Naber KG, Hofstetter AG, Bruhl P. et al. Guidelines for the perioperative prophylaxis in urological interventions of the urinary and male genital tract. Int J Antimicrob Agents 2001; 17: 321-326
22 Muller CS, Hubner W, Thieme-Ruffing S. et al. Pre- and perioperative aspects of dermatosurgery. J Dtsch Dermatol Ges 2017; 15: 117-146
23 Salasche SJ. Acute surgical complications: cause, prevention, and treatment. J Am Acad Dermatol 1986; 15: 1163-1185
24 Saleh K, Schmidtchen A. Surgical site infections in dermatologic surgery: etiology, pathogenesis, and current preventative measures. Dermatol Surg 2015; 41: 537-549
25 Balakirski G, Felcht M, Bayer H. et al. Analysis of the status quo of perioperative antibiotic prophylaxis in dermatosurgery in Germany: results of the DESSI-study. J Dtsch Dermatol Ges 2019; 17: 703-713
26 Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence?. Br J Dermatol 2008; 158: 442-455
27 Cruse PJ, Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980; 60: 27-40
28 Wacha H, Hoyme U, Isenmann R. et al. Perioperative Antibiotika-Prophylaxe. Empfehlungen einer Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Chemother J 2010; 19: 70-84
29 Wolters U, Wolf T, Stutzer H. et al. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth 1996; 77: 217-222
30 Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl 2011; 93: 185-187
31 Wright TI, Baddour LM, Berbari EF. et al. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008. J Am Acad Dermatol 2008; 59: 464-473
32 Kulichova D, Geimer T, Muhlstadt M. et al. Surgical site infections in skin surgery: a single center experience. J Dermatol 2013; 40: 779-785
33 Prävention postoperativer Infektionen im Operationsgebiet. Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Bundesgesundheitsbl Gesundheitsf Gesundheitsschutz 2007; 50: 377-393
34 Johnson-Jahangir H, Agrawal N. Perioperative antibiotic use in cutaneous surgery. Dermatol Clin 2019; 37: 329-340
35 Muhlstadt M, Kulichova D, Kunte C. Perioperative Antibiotikaprophylaxe in der Dermatochirurgie. Update 2009. Hautarzt 2009; 60: 546-549
36 Haas AF, Grekin RC. Antibiotic prophylaxis in dermatologic surgery. J Am Acad Dermatol 1995; 32: 155-176; quiz 177–180
37 Cherian P, Gunson T, Borchard K. et al. Oral antibiotics versus topical decolonization to prevent surgical site infection after Mohs micrographic surgery -- a randomized, controlled trial. Dermatol Surg 2013; 39: 1486-1493
38 Cordova KB, Grenier N, Chang KH. et al. Preoperative methicillin-resistant Staphylococcus aureus screening in Mohs surgery appears to decrease postoperative infections. Dermatol Surg 2010; 36: 1537-1540
39 Bari O, Eilers Jr RE, Rubin AG. et al. Clinical Characteristics of Lower Extremity Surgical Site Infections in Dermatologic Surgery Based Upon 24-Month Retrospective Review. J Drugs Dermatol 2018; 17: 766-771
40 Levin EC, Chow C, Makhzoumi Z. et al. Association of postoperative antibiotics with surgical site infection in mohs micrographic surgery. Dermatol Surg 2019; 45: 52-57
41 Smith SC, Heal CF, Buttner PG. Prevention of surgical site infection in lower limb skin lesion excisions with single dose oral antibiotic prophylaxis: a prospective randomised placebo-controlled double-blind trial. BMJ Open 2014; 4: e005270
42 Wilson W, Taubert KA, Gewitz M. et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116: 1736-1754
43 Classen DC, Evans RS, Pestotnik SL. et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326: 281-286
44 Lee MR, Paver R. Prophylactic antibiotics in dermatological surgery. Australas J Dermatol 2016; 57: 83-91
45 Hamburg AK. Studie: „Patientensicherheit – worauf es Patienten ankommt“. 2015 Im Internet: https://www.asklepios.com/presse/presse-mitteilungen/konzernmeldungen/studie-patientensicherheit-worauf-es-patienten-ankommt~ref=eb4b30af-4bd6-4365-9b67-31baebfb4962~
46 Meyer E, Schroder C, Gastmeier P. et al. The reduction of nosocomial MRSA infection in Germany: an analysis of data from the Hospital Infection Surveillance System (KISS) between 2007 and 2012. Dtsch Arztebl Int 2014; 111: 331-336
47 Siegmund-Schultze N. Antibtiotikaresistenzen in Deutschland: Spektrum an Problemkeimen wächst. Dtsch Ärztebl 2016; 113: A655ff
48 Hygienemaßnahmen zur Prävention der Infektion durch Enterokokken mit speziellen Antibiotikaresistenzen. Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsblatt 2018; 61: 1310-1361 Im Internet: https://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/Enterokokken_Rili.pdf?__blob=publicationFile
49 Empfehlungen zur Prävention und Kontrolle von Methicillin-resistenten Staphylococcus aureus-Stämmen (MRSA) in medizinischen und pflegerischen Einrichtungen. Empfehlungen der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert-Koch-Institut. Bundesgesundheitsblatt 2014; 57: 696-732 Im Internet: https://www.rki.de/DE/Content/Infekt/Krankenhaushygiene/Kommission/Downloads/MRSA_Rili.pdf?__blob=publicationFile
50 Daeschlein G, von Podewils S, Bloom T. et al. Risk factors for MRSA colonization in dermatologic patients in Germany. J Dtsch Dermatol Ges 2015; 13: 1015-1022
51 Suh L, Coffin S, Leckerman KH. et al. Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol 2008; 25: 528-534
52 Schlotthauer U, Schulze-Röbbecke R. Vertikale und horizontale Präventionsstrategien. Krankenhaushyg Up2date 2017; 12: 379-394
53 Gebhardt FE, Wantia N. Prävention nosokomialer Infektionen durch Bündel. Evidenz und praktische Umsetzung. Med Klin Intensivmed Notfmed 2013; 108: 119-124
54 Harris J, Walsh K, Dodds S. Are contact precautions ethically justifiable in contemporary hospital care?. Nurs Ethics 2019; 26: 611-624
55 Mehrotra P, Croft L, Day HR. et al. Effects of contact precautions on patient perception of care and satisfaction: a prospective cohort study. Infect Control Hosp Epidemiol 2013; 34: 1087-1093
56 Lemmen SW, Lewalter K. Antibiotic stewardship and horizontal infection control are more effective than screening, isolation and eradication. Infection 2018; 46: 581-590
57 Im Internet: https://www.nak-deutschland.org/tl_files/nak-deutschland/NeueBedeutungi_20181122_final.pdf
58 McAdam AJ. The divergent meanings of „I“ for the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial susceptibility testing: a micro-comic strip. J Clin Microbiol 2019; 57: e00050-19
59 Midtvedt T. The microbial threat. Berlin: Blackwell Verlag; 1998